Hsbc Holdings PLC Has $844,000 Stock Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Hsbc Holdings PLC lessened its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 33.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 43,209 shares of the company's stock after selling 21,858 shares during the quarter. Hsbc Holdings PLC's holdings in Privia Health Group were worth $844,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. raised its stake in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after buying an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in Privia Health Group by 7,833.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock worth $47,000 after acquiring an additional 2,350 shares during the period. Financial Management Professionals Inc. bought a new position in shares of Privia Health Group in the 4th quarter worth about $51,000. Quadrant Capital Group LLC raised its position in shares of Privia Health Group by 11.8% in the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company's stock worth $95,000 after acquiring an additional 511 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Privia Health Group by 185.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,999 shares of the company's stock valued at $98,000 after purchasing an additional 3,249 shares in the last quarter. Institutional investors own 94.48% of the company's stock.

Privia Health Group Price Performance

PRVA opened at $23.32 on Monday. Privia Health Group, Inc. has a fifty-two week low of $15.92 and a fifty-two week high of $26.04. The company's 50-day moving average is $23.50 and its 200 day moving average is $22.12. The firm has a market capitalization of $2.83 billion, a P/E ratio of 233.22, a PEG ratio of 3.47 and a beta of 0.88.

Insiders Place Their Bets

In other Privia Health Group news, CFO David Mountcastle sold 3,445 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $80,371.85. Following the completion of the transaction, the chief financial officer now owns 176,231 shares in the company, valued at $4,111,469.23. This represents a 1.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Matthew Shawn Morris sold 10,309 shares of Privia Health Group stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total value of $240,508.97. Following the sale, the director now owns 59,792 shares in the company, valued at $1,394,947.36. The trade was a 14.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,484 shares of company stock valued at $799,163 in the last 90 days. 10.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on PRVA. JMP Securities reiterated a "market outperform" rating and issued a $29.00 target price on shares of Privia Health Group in a report on Monday, April 28th. Piper Sandler raised their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Barclays upped their price objective on shares of Privia Health Group from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Thursday, April 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 target price on shares of Privia Health Group in a research report on Thursday, April 10th. Finally, Robert W. Baird increased their price target on Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a report on Tuesday, April 15th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $27.38.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.